World Preclinical Congress
June 17-20, 2019. Boston, MA
Meet Us at WPC2019 and See How NeuCyte can Help Accelerate Your CNS Drug Discovery,
Efficacy and Safety Assessment
Booth 233
Join our scientific presentations
Beyond iPSC Based Disease Models:
A Translatable Drug Discovery Platform for Status Epilepticus
Epilepsy is a common neurological disorder characterized by recurrent spontaneous seizures. About 30% of patients do not respond or develop resistance to available anti-epileptic drug treatments. The establishment of more translatable human cell-based assays can address the unmet need for new therapy strategies by complementing pre-clinical drug development to increase success rates in human patients. NeuCyte has built an iPSC-derived neural in vitro platform with complex electrophysiology-based phenotypic readouts to evaluate the efficacy of novel compounds and approved AEDs for the treatment of Status Epilepticus.
Date: June 18th
Time: 2:10pm
Room: Cityview 1
Daniel Haag, PhD
CSO and Co-Founder, NeuCyte
Overcoming Challenges in CNS Drug Discovery through Developing Translatable iPSC-derived Cell-Based Assays
Using direct reprogramming of iPSCs to generate defined human neural tissue, NeuCyte developed cell-based assays with complex neuronal structure and function readouts for versatile pre-clinical applications. Focusing on electrophysiological measurements, we demonstrate the capability of this approach to identify adverse neuroactive effects, evaluate compound efficacy, and serve phenotypic drug discovery.
Date: June 20th
Time: 1:00pm
Room: Harborview 1
Jonathan Dávila, PhD
CTO and Co-Founder, NeuCyte
View our Scientific Poster
Implementation of Human iPSC-derived Neural Cultures in CNS Drug Discovery
June 18-20